The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

@article{vanEde2001TheCM,
  title={The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.},
  author={Annelies E van Ede and Roland F J Laan and Henk J Blom and Twj Huizinga and Cees J. Haagsma and Belinda A J Giesendorf and T M de Boo and Levinus B A van de Putte},
  journal={Arthritis and rheumatism},
  year={2001},
  volume={44 11},
  pages={
          2525-30
        }
}
OBJECTIVE To study the possible relationship between the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and the toxicity and efficacy of treatment with methotrexate (MTX) in patients with rheumatoid arthritis (RA). METHODS Genotype analysis of the MTHFR gene was done in 236 patients who started MTX treatment with (n = 157) or without (n = 79) folic or folinic acid supplementation. Outcomes were parameters of efficacy of MTX treatment, patient withdrawal due to adverse… Expand

Paper Mentions

Observational Clinical Trial
Methotrexate is a cornerstone in the treatment of childhood leukemia. When given in high-dose as part of the initial phase of treatment, gastrointestinal toxicity is a known problem… Expand
ConditionsALL, Juvenile Idiopathic Arthritis
Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation.
TLDR
It is suggested that C677T polymorphism in the MTHFR gene is not predictive of toxicity or efficacy of MTX treatment in RA patients receiving folate supplementation. Expand
The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population
TLDR
It is demonstrated that the C677T polymorphism in the MTHFR gene is associated with MTX toxicity in a Spanish RA population. Expand
2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
TLDR
In the population of MTX-treated RA patients the 2756GG genotype of the MTR gene was more common than expected and was associated with MIARN, and no association of disease activity variables or plasma homocysteine with MTR A2756G polymorphisms was observed. Expand
Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases
TLDR
The identification of MTHFR genotypes for C677T and A1298C polymorphisms could lead clinicians to identify patients in risk of elevation of transaminases, and give them an individualized treatment, as is a goal of pharmacogenetics. Expand
Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis
We investigated associations between the methylenetetrahydrofolate reductase (MTHFR) polymorphisms C677T and A1298C and methotrexate (MTX)-related toxicities in Korean patients with rheumatoidExpand
The Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity
TLDR
A1298C and C677T polymorphisms in the MTHFR gene, were not related with MTX-related toxicity in RA patients receiving folate supplementation, and were found to be similar in patients with and without MTx-related adverse events. Expand
Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients
TLDR
The study suggests that MTHFR C677T and A1298C genotyping are associated to MTX toxicity and efficiency, respectively, in RA patients, which offers new perspectives in the personalization of RA treatment in Algeria. Expand
Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene.
TLDR
The A1298C polymorphism of the MTHFR gene may indicate a need to adjust the dose of methotrexate given to patients with rheumatoid arthritis. Expand
Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients?
TLDR
The findings do not suggest a significant association of MTHFR/TS allele/genotype with MTX response in the authors' ethnically distinct Indian (Asian) RA patients. Expand
677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.
TLDR
The results of this study suggest that the MTHFR 677T and 1298C alleles may be associated with an increased rate of RA remission in patients treated with MTX receiving high doses of folic acid supplementation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
TLDR
This work has identified a common mutation in MTHFR which alters a highly-conserved amino acid; the substitution occurs at a frequency of approximately 38% of unselected chromosomes and may represent an important genetic risk factor in vascular disease. Expand
Is the common 677C-->T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis.
TLDR
A meta-analysis confirms that the 677C-->T mutation is a genetic risk factor for NTD. Expand
Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
TLDR
A persistent increase in plasma homocysteine concentrations was observed in patients treated with MTX alone and more pronounced in combination with SSZ, in contrast withSSZ alone. Expand
Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects.
TLDR
Red cell folate levels decrease during MTX treatment and relate to side effects, withdrawals, liver enzyme elevations and aberrant MTX dosage increase, but not to the therapeutic effect. Expand
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
TLDR
Both folate supplementation regimens reduced the incidence of elevated liver enzyme levels during MTX therapy, and as a consequence, MTX was discontinued less frequently in these patients. Expand
Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.
TLDR
In 28% of the hyperhomocysteinemic patients with premature vascular disease, abnormal homocysteine metabolism could be attributed to thermolabile MTHFR. Expand
Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity.
TLDR
An update of the current knowledge of the mechanism of action of low-dose methotrexate (MTX) in the treatment of patients with rheumatoid arthritis (RA), with an emphasis on the mechanisms involved in toxicity. Expand
The mechanism of action of methotrexate.
  • B. Cronstein
  • Medicine
  • Rheumatic diseases clinics of North America
  • 1997
TLDR
Evidence is reviewed that favors the notion that the endogenous anti- inflammatory autocoid adenosine mediates the anti-inflammatory effects of methotrexate. Expand
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.
An investigation of clinical and laboratory variables which might form the basis for judging disease activity in clinical practice was made by six rheumatologists in a prospective study of up toExpand
Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity
TLDR
The effect of methotrexate on in vivo rheumatoid factor production and suppression of ex vivo leukotriene B4 generation is reviewed and new information on drug interactions and pharmacokinetics is highlighted. Expand
...
1
2
...